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The purpose of this study was to investigate the effect of photothermal treatment (PTT) with gold nanoshell (ANS) using a
macrophage-mediated delivery system in a head and neck squamous cell carcinoma (HNSCC) cell line. To achieve this, ANS-
loaded rat macrophages (ANS-MAs) were prepared via the coculture method with ANS. The human HNSCC (FaDu cell) and
macrophage (rat macrophage; NR8383 cell) hybrid spheroid models were generated by the centrifugation method to
determine the possibility of using ANS-MAs as a cancer therapy. These ANS-MAs were set into the tumor and
macrophage hybrid spheroid model to measure PTT efficacy. Kinetic analysis of the spheroid growth pattern revealed that
this PTT process caused a decreasing pattern in the volume of the hybrid model containing ANS-MAs (p < 0:001).
Comparison with empty macrophages showed harmony between ANS and laser irradiation for the generation of PTT. An
annexin V/dead cell marker assay indicated that the PTT-treated hybrid model induced increasing apoptosis and dead
cells. Further studies on the toxicity of ANS-MAs are needed to reveal whether it can be considered biocompatible. In
summary, the ANS was prepared with a macrophage as the delivery method and protective carrier. The ANS was
successfully localized to the macrophages, and their photoabsorption property was stationary. This strategy showed
significant growth inhibition of the tumor and macrophage spheroid model under NIR laser irradiation. In vivo toxicology
results suggest that ANS-MA is a promising candidate for a biocompatible strategy to overcome the limitations of
fabricated nanomaterials. This ANS-MA delivery and PTT strategy may potentially lead to improvements in the quality of
life of patients with HNSCC by providing a biocompatible, minimally invasive modality for cancer treatment.
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1. Introduction
Photo-based therapy is a newly developed therapeutic strat-
egy with unique advantages including high specificity, min-
imal invasiveness, and precise spatial-temporal selectivity.
Photothermal therapy (PTT), a type of photo-based therapy,
has been developed for the eradication of cancer cells in the
primary tumor and the initial stage of cancer metastasis.
PTT can also be combined with current therapies to
improve their therapeutic outcomes [1–4]. The therapeutic
efficacy of PTT depends on the transformation of light to
sufficient heat with photothermal agents such as metal
nanostructures, nanocarbons, and organic agents [1]. Metal-
lic nanoparticles are preferable photothermal agents due to
their potential applications with tunable optical activities.
Metallic nanoparticles have unique optical properties due
to the interaction between light and the free conduction-
band electrons on the surface of the particles. The electric
field causes the collective oscillation of the conduction-
band electrons on the surface of the nanoparticles under
suitable light conditions. This phenomenon, termed surface
plasmon resonance (SPR), makes metallic nanoparticles
attractive to cancer treatment researchers [5]. Many
researchers have tried to improve the inherent properties
of the metallic nanoparticles by employing several strategies
such as changing the nanostructure and using multiple
metallic compound combinations. The combination of the
Fe7S8 and Bi2S3 metallic compounds helps create a large sur-
face area for effective drug loading and provides high NIR
absorption for enhanced photothermal efficacy [3]. Thus,
the combination of the two metal structures showed 1.54
times higher NIR absorption intensity than that of pure
Bi2S3 nanomaterials [3]. Zhang et al. have developed the
superstructure of CuS for use in chemo-photothermal ther-
apy; this CuS was biodegradable, which enabled its use in
synergistic chemo-photothermal therapy [4].
Gold-silica nanoshells, a type of gold-based nanoparti-
cle, are excellent PTT agents due to optimum absorption,
significant penetration in biological tissues under NIR
light, and high optical-to-thermal energy conversion effi-
ciency, approximately one million times higher than indo-
cyanine green [5, 6]. The gold-silica nanoshells, first
described by Oldenburg et al. [7], are obtained by using a sil-
ica core (50-500 nm) and gold layer (5-20 nm) to improve
photothermal efficacy [8]. Hirsch et al. [9] demonstrated
the potential of PTT by using gold-silica nanoshells with sev-
eral in vitro studies on a variety of cancer cell lines, such as
the human breast, prostate, brain, and liver [10].
While the gold nanoshell was the infeasible factor dur-
ing target delivery to the tumor, other concerns include a
vague evaluation of gold nanoshells in the toxicity study
and the limitation of their efficacy in tumors [11]. The
main reason for this issue is that bare nanoparticles are
structurally limited by the heterogeneous tumor microenvi-
ronment, which prevents nanoparticles, including drugs,
from entering deep into the extravascular tumor tissue.
Malignant solid tumors consist of dense tumor cells that
restrict the space for angiogenesis, resulting in tortuous
and dysfunctional vasculatures that produce irregular blood
supply, high interstitial fluid pressure (IFP, 10-100mm Hg),
and a compact extracellular matrix within tumor tissue [12,
13]. Moreover, the systemic administration of anticancer
agents produces generalized or organ-specific toxicity in
the patients. As a result, a cancer-targeted delivery system
is urgently needed [11, 14].
The targeted delivery of nanoparticles is a challenging
modality for bioimaging and cancer treatments. Nanoparti-
cles may increase the efficacy of chemotherapeutics while
decreasing undesired side effects. In the nanoparticle-based
targeted delivery field, many researchers have tried several
approaches to improve delivery efficacy, including biode-
gradable and biocompatible polymerization or the attach-
ment of an antibody to a target (a specific organ or cell)
[15]. However, many nanomedicine applications that are
based on targeted delivery and therapy have limitations,
including insufficient accumulation at the target site, uncon-
trolled accumulation in normal tissue, cell toxicity, and rapid
elimination. To overcome these limitations, cancer therapies
using immune cells have recently been proposed in which
immune cells function as vectors or carriers for the delivery
of therapeutic agents [6, 11, 16–18].
The biomimetic delivery system (BDS) has been emerg-
ing as a novel strategy due to its inherent tumor-homing ten-
dency and biocompatibility [19]. The basic theory of BDS is
the chemotaxis of certain cells; a variety of cytokines secreted
by tumor cells attract immune cells, which accumulate in
tumor sites. This strategy uses the isolated macrophages, T
cells, or mesenchymal stem cells (MSCs) from peripheral
blood or tumor samples, which are modified or loaded with
therapeutic agents and infused back into patients to perform
the treatment [17]. Recent studies also characterized immune
infiltrates in the tumor microenvironment of HNSCC. This
research suggests improved patient survival and high levels
of intratumoral immune cell infiltrates [20]. Macrophages,
which are circulating cells, are recommended by many stud-
ies for the treatment of tumors because the use of monocy-
tes/macrophages provides several advantages compared to
MSCs: they can be easily obtained from the patient, easily
loaded into therapeutic drugs or nanoparticles, and rein-
jected into the bloodstream [5, 11, 21, 22]. Additionally, mac-
rophages naturally penetrate tumor tissue due to the fact that
tumor-associated macrophages (TAM) are one of the most
prominent components of tumor mass (up to 50%) [11, 23].
In this study, the gold nanoshell-loaded macrophage
(ANS-MA) system was selected as a therapeutic agent to treat
HNSCC. The PEGylation of gold nanoshell (ANS) was used
to increase the uptake ratio of ANS and to give the macro-
phage a nontoxic property [5]. The macrophage was chosen
as the delivery vector to target the HNSCC, since it can pro-
vide biocompatibility and targeted delivery, and it does not
degrade in the body fluid environment [24]. The HNSCC
tumor cell (FaDu cell) and macrophage hybrid models were
used to mimic tumor environments, such as TAM, and to
determine therapeutic efficacy under the 810nm laser light
generated by PTT. This macrophage-based targeted delivery
system may provide an enhanced target delivery system for
cancer therapy in the medical and pharmacological fields
[16–18]. The macrophage and ANS hybrid system works
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synergistically to optimize target delivery and improve the
therapeutic outcome of HNSCC treatment.
2. Materials and Methods
2.1. Materials. FaDu cells (human head and neck squamous
cell carcinoma: HNSCC, ATCC, and HTB-43) were grown
in Dulbecco’s Modified Eagle Medium (DMEM, Gibco,
Carlsbad, CA) with high glucose (Invitrogen Corp., Carlsbad,
CA) supplemented with 10% fetal bovine serum (FBS, Gibco,
Carlsbad, CA), 2mM L-glutamine, and 100mg/ml gentamy-
cin. Rat alveolar macrophages (NR8383; ATCC, CRL-2192)
were maintained in DMEM with high glucose supple-
mented with 10% FBS, 25mM HEPES buffer (Gibco,
Carlsbad, CA) (pH7.4), 100U/ml penicillin, and 100mg/ml
streptomycin. All cultures were maintained at 37°C and
7.5% CO2. The gold nanoshells (ANS, Nanospectra Biosci-
ences, Inc., Houston, TX) used in this study consist of a
120nm diameter silica core surrounded by a 12 to 15 nm
thick gold shell. The nanoshells are PEGylated to inhibit
aggregation and have peak absorption between 800 and
810nm (Figure 1(b)).
2.2. Uptake of ANS by Macrophages. Macrophages were
prepared in a 50ml conical tube with 1 × 106 cell/10ml
of culture medium concentration. After overnight incuba-
tion, macrophages were detaching to the plastic, all of
the media exchanging to 10ml of fresh culture media with
50μl of PEGylated ANS colloid (2:8 × 1011 particles/ml).
ANS-MAs were rinsed three times by Hanks’ Balanced
Salt Solution (HBSS) with calcium chloride and magne-
sium chloride (Gibco, Carlsbad, CA) to remove excess
noningested ANS. ANS-MAs were detached by using Try-
pLE Express (Invitrogen, Carlsbad, CA). ANS-MAs were
confirmed by phase contrast microscopy and holographic
images and the ANS location identified in the macrophage
by the gold ion detection with scanning electron micros-
copy (SEM, JSM-7610F, JEOL, Akishima, Japan).
2.3. Photothermal Conversion Efficiency of ANS-MAs. To
measure the photothermal conversion efficiency, the
nanoparticle solution was placed in a 1 cm path length
quartz cuvette. The temperature change in response to
irradiation with an 810nm laser was measured using a
thermometer (IR meter, DH. the3017 DAIHAN Scientific,
Wonju, Korea).
Photothermal conversion efficiency was calculated using
the following:
Photothermal conversion efficiency = hA Tmax − Tsurrð Þ −Qdis
I 1 − 10−Aλ
  ,
ð1Þ
where “h” indicates the heat transfer coefficient and “A” indi-
cates the surface area of the container. Tmax and Tsurr indicate
the maximum temperature of the sample (Tmax) and sur-
rounding temperature (Tsurr), respectively. Qdis indicates
the heat dissipated from the light absorbed by the quartz cell
(37.8mW). “I” indicates incident laser power, and Aλ indi-
cates the absorbance of ANS-MAs at 810nm. The “hA” was
calculated by following:
hA = mDcD
τ
, ð2Þ
where mD (1 g) and cD (4.2 J/g
°C) indicate the mass and
heat capacity of deionized water and τ indicates the sys-
tem time constant. Then, we calculated the thermal time
constant using
t = −τ ln ΔT
ΔTmax
 
, ð3Þ
where ΔT indicates the temperature change, i.e., tempera-
ture difference between the sample temperature and sur-
rounding temperature. ΔTmax indicates the maximum
steady-state temperature.
2.4. Hybrid Tumor and Macrophage Spheroids. The tumor
cell and macrophage spheroid preparation method was first
described by Ivascu and Kubbies [25]. Following the
described method, spheroid formation was generated by
ultralow attachment surface 96-well round-bottomed plates
(Corning Inc., NY) with4 × 103cells per 200μl culture media
in each well. Macrophages were mixed with tumor cells at
ratios of tumor cell: macrophage follows 4 : 1, 5 : 1, 8 : 1, and
10 : 1. Empty or ANS-MAs were pretreated with mitomycin
C to prevent cell division before mixing with tumor cells.
The prepared cell mixture was centrifuged at 1,000× g for
10min. The tumor cells and macrophages formed a disk
shape immediately after centrifugation. The tumor cell and
macrophage cell spheroids were subsequently maintained in
a 37°C CO2 incubator for 48 hours to allow the cells to
assume a typical three-dimensional spheroid form. And
hybrid tumor and macrophage spheroid sizes were acquired
at 2, 5, 8, 12, and 16 days to get a growth pattern. The hybrid
spheroid volume was calculated by the following equation:
Hybrid spheroid volume = 43 × 3:14 ×
spheroid diameter
2
 3
:
ð4Þ
2.5. Photothermal Treatment. Hybrid spheroids contain-
ing either empty macrophage or ANS-MAs were treated
with PTT and allowed to grow in culture for 19 days to
determine their viability. Hybrid spheroids were formed
from a mixture of 4 × 103 tumor cells and 1 × 103 empty
macrophage or ANS-MAs. After the 4-day incubation
time, each spheroid was generated by photothermal ther-
apy under the 810 nm laser light (Coherent Inc., Santa
Clara, CA) irradiation at 14W/cm2 with a 3mm diame-
ter laser spot for 10min. We measured the diameter of
the spheroids with a microscope and calculated the volume
(volume = 4/3 × 3:14 × ðspheroid diameter/2Þ3) of the spher-
oids for 19 days.
2.6. In Vitro Apoptosis Assay. In vitro apoptosis assay was
measured using Muse® Annexin V Dead Cell Kit (Millipore
3BioMed Research International
Corporation, USA). The hybrid spheroids were generated in
ultralow attachment surface 96-well round-bottomed plates
(Corning Inc., NY) with 4 × 103 cells in 200μL culture
medium per well. Subsequently, 810 nm laser irradiated to
the hybrid spheroid for 10min at 14W/cm2. After 24 hours
of incubation time, the cells were then washed twice with
PBS and incubated with 100μL of Muse® Annexin V at room
temperature for 20min. The percentage of apoptosis induc-
tion was quantified by using MUSE (Millipore Corporation,
USA). The experiment was repeated three times.
2.7. Hemolysis Study of ANS-MAs. Red blood cells (RBCs)
were obtained from 6-7-week-old SD rats purchased from
Orient Bio Inc. (Seoul, South Korea). The RBCs were
Silica
core
Gold layer
PEGylation coating
Gold nanoshell Rat macrophage
Phagocytosis
ANS-MAs
Silica
core
Silica
core
Silica
core
Silica
core
Silica
core
(a)
400 500 600 700 800 900
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
A
bs
ro
ba
nc
e (
A
bs
)
Wavelength (nm)
Gold nanoshell
(b)
Empty macrophage ANS-MAs
(c)
–30 –1020 0
X-Axis
Y-
A
xi
s
10 20 30
–30
–10
20
0
10
20
30
(d)
Figure 1: (a) Schematic image exhibits the constitution of ANS and ANS-loaded rat alveolar macrophage cells. (b) UV-visible spectrum of
ANS, which exhibits a maximum absorption peak at 800–810 nm. And SEM image shows ANS size (152~162 nm) and globular
morphology. (c) Phase-contrast microscopic images of empty macrophage and ANS-MAs. The macrophage cells were loaded with ANS
by a coculture method for 24 hours (scale bar denotes 100 μm). (d) Holography image of 3D ANS-MAs. Red dots (and red arrow)
indicated the ANS location (ANS: gold nanoshell; ANS-MAs: gold nanoshell-loaded macrophages).
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incubated with PBS (positive control), macrophages, ANS-
MAs, and 0.03% Triton® X-100 (negative control) for 3 hours
and then isolated by centrifugation (1,400 rpm, R.T.). The
absorbance of free hemoglobin released in the supernatant
was measured at 541 nm using UV-visible spectroscopy
(OPTIZEN IV, Mecasys Co. Ltd., South Korea).
2.8. Complete Blood Count (CBC) and Serum Biochemistry
Analysis. All animal experiments were performed under the
guidelines of the Chonnam National University Medical
School Research Institutional Animal Care Committee, and
all the experimental protocols were approved by the commit-
tee. For the CBC and serum biochemistry analysis, ANS-
MAs were intravenously injected into SD rats (6–7 weeks
old). The rats (N = 5) were maintained under specific
pathogen-free conditions, and blood samples were collected
from the heart when the rats were under anesthesia at 0, 1,
7, and 21 days. Whole blood was collected in K2 EDTA
5.4mg and SSTTM (BD Vacutainer®, Franklin Lakes, USA)
tubes to prevent coagulation; 2ml of the collected blood
was used for the CBC analysis, and 3ml of the collected blood
was used for the serum biochemistry analysis. We then ana-
lyzed the total number of RBC, WBC, Hct, Hb, and platelets
and determined the serologic parameters related to liver and
kidney functions, including the level of various enzymes,
such as albumin, ALP, ALT, AST, BUN, creatinine, globulin,
total protein, T.Bil, and γ-GTP.
RBC stands for red blood cell, WBC for white blood cell,
Hct for hematocrit, Hb for hemoglobin, ALP for alkaline
phosphatase, ALT for alanine aminotransferase, BUN for
blood urea nitrogen, T.Bil for total bilirubin, and γ-GTP for
gamma-glutamyl transferase.
2.9. Histological Analysis. The harvested hearts, lungs, livers,
and kidneys of the rats were fixed with 8% paraformaldehyde
for 4 hours after washing with saline. The samples were then
dehydrated and embedded in paraffin, sectioned (4μm), and
stained with hematoxylin and eosin. The stained slides were
examined by light microscopy with ×40 (heart) and ×100
(lung, liver, and kidney) magnifications. To determine the
toxicity of the ANS-MAs, histological analysis of each organ
was performed and showed whether macrophage and ANS
caused tissue damage and/or any pathologic impacts such
as inflammation or necrosis.
2.10. Statistical Analysis. Data are presented as mean ±
standard deviation of results obtained from three indepen-
dent trials unless otherwise indicated. Analysis of variance
(ANOVA) (OriginPro8) was utilized to determine statistical
significance between three or more groups, respectively.
p values < 0.05 were considered statistically significant.
3. Results
3.1. ANS-MA Preparation. PEGylated ANS was characterized
by UV-vis spectrometry, SEM, TEM, and X-ray diffraction
(XRD) analysis. UV-vis spectra showed the maximum
absorption peak at 800–810nm for laser treatment
(Figure 1(b)). SEM and TEM imaging revealed ANS size
(152:0 ± 8:8 nm) and globular morphology (Figures 1(b)
and S1). The structure of ANS was confirmed using XRD
analysis (D2 Phaser, Bruker, Massachusetts, US). Diffraction
peaks were observed at 2θ = 38:196, 44.395, 64.592, 77.587,
and 81.744. Each peak indicated that the ANS had a struc-
ture similar to that of gold nanoparticles. In the XRD analy-
sis, this ANS exhibited characteristic peaks at 2θ = 77:587
and 81.744, which correspond to those of a silica core
(Figure S2). ANS-MAs (NR8383) were observed by phase-
contrast microscopy and holographic analysis after a 24-
hour incubation period. In Figure 1(c), the black dots
indicate ANS accumulation in the macrophage. These dark
areas are absent in the control macrophages that were not
incubated with ANS. Holographic images (Figures 1(d)
and Video 1) show ANS uptake more clearly with 3D
images based on the reflective index (ANS RI: 1.334-1.342).
In these images, ANS can be differentiated from other
vesicles or lipid droplets. SEM and EDX images detected
gold ions located in the ANS-MAs, and they show that
ANS are mainly distributed in the cell cytoplasm (Figure 2).
These microscopic, holographic, and EDX images indicate
that the ANS were successfully inserted into the
macrophage and their physical properties were safely
maintained after the cell loading process. Additionally, the
mass extinction coefficients for the ANS and ANS-MAs
were 4.83 L(g cm)-1 and 4.77 L(g cm)-1, respectively. The
similarity between the mass extinction coefficients for the
ANS and ANS-MAs indicates that there is negligible
interference of the macrophage caging system on the NIR
absorption of the ANS.
3.2. Hybrid Spheroid Preparation and PTT Study. The heat
generation effect of ANS-MAs has been shown in
Figure S3A. The temperature of ANS-MAs reached 51.1°C
within 10min in response to laser irradiation. The system
time constant (τ) shown in Figure S3B was calculated
using the linear fitting graph of the cooling time and
temperature change data. Based on these two results, we
calculated the photothermal conversion efficiency of
ANS-MAs. We calculated the photothermal conversion
efficiency of ANS-MAs to be 41.49%. Additionally, the
photothermal effects of ANS-MAs were maintained until
5 cycles of laser treatment (Figure S3C). The hybrid
spheroid model containing FaDu cells (Human HNSCC)
and macrophages was produced by the centrifugation method
with two ratios (FaDu : Ma = 8 : 1 and 4 : 1). ANS-MA
behavior in tumor spheroids was observed via two-photon
fluorescence images of cytoplasm stained with PKH26
(Figure 3(a); FaDu : Ma = 4 : 1). The growth patterns of the
tumor and macrophage hybrid models, both with and without
ANS applied, are shown in Figure 3(b). A slight increase from
the 12.5% macrophage (FaDu : Ma = 8 : 1) to the 25%
macrophage (FaDu : Ma = 4 : 1) occurred due to the different
sizes between FaDu cells and macrophages. The growth ratio
was not restrained with the addition of ANS.
ANS-MAs induce the heat and destruction of tumor cells
in the tumor and ANS-MA hybrid models. This phenome-
non depends on the ratio of ANS-MAs. PTT efficacy is high-
est in 25%macrophages (FaDu : Ma = 4 : 1) of all the various
tumor-to-macrophage ratios (FaDu control, empty Ma,
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FaDu : Ma = 10 : 1, 8 : 1, 5 : 1, and 4 : 1) under laser treatment
(Figure 4(a)). The tumor and ANS-MA hybrid model volume
growth pattern is shown in Figure 4(b). This graph demon-
strates that ANS-MAs are the key factor for therapeutic
agents under laser irradiation. This PTT process caused a sig-
nificant decrease in the volume of the hybrid model contain-
ing ANS-MAs (p < 0:001). For the other groups, the ANS-
MA treatment or laser treatment with empty macrophages
(without ANS) was used for comparison. Those comparisons
show the importance of the synergy of ANS and laser treat-
ment and the inefficacy of either process alone.
An annexin V/dead cell marker assay was performed
to confirm the induction of apoptosis and debris cell ratio
in the tumor and ANS-MAs hybrid models. As shown in
Figure 5, the ANS-MAs exhibited increased apoptosis acti-
vation compared to the FaDu cell spheroid model. The
total apoptosis results were 44:0 ± 1:5% and 64:8 ± 3:0%
for cells consisting of 20% (FaDu : Ma = 5 : 1) and 25%
(FaDu :Ma=4 : 1) macrophage, respectively. Notably, the
hybrid model with the ANS-MA ratio of 25%
(FaDu : Ma = 4 : 1) showed an increase in the late apopto-
sis and death and a decrease in the early apoptosis.
3.3. Toxicology Study of AuNP-Loaded Macrophage Using a
Balb/c Rat Model. The hemolysis of RBCs was measured after
3 hours of exposure to different macrophage concentrations
with or without ANS. The absorbance of free hemoglobin
released from RBCs through a PBS and Triton X-100 solu-
tion was measured using a multiscan reader as shown in
Figure S4. The average hemoglobin absorbance of each
ANS-MA was less than 0.1, similar to the positive control
(PBS). These results indicate that ANS-MAs do not destroy
RBCs and are nontoxic in vascular environments.
For the in vivo toxicology study, blood circulation half-
time of ANS-MAs was calculated. The intensity of the Au
ions decreased after 6 hours (maximum intensity time) post-
injection, and Au ions completely become extinct at 24 hours
postinjection. Based on this result, we conclude that ANS-
MAs have a half-life of 12 hours in the blood. In vivo cytotox-
icity studies of ANS-MAs were performed on the rat model
for 21 days. The ANS-MAs were suspended in PBS and
injected into the tail vein. Blood was collected from the heart
before injection and at 1, 7, and 21 days postinjection. We
sought to determine any toxicity, immune system alteration,
or negative profiles that could result from metal- or drug-
loaded macrophages as a result of their use as therapeutic
or diagnostic vehicles. As shown in Figure 6, the ALP was sig-
nificantly lower prior to the injection of ANS-MAs, and the
ALT slowly increased until day 7, before reverting back to a
normal value at day 21. The homeostasis of ALP, ALT, and
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Figure 2: SEM image and EDX graph of the empty macrophage and ANS-MAs demonstrate that 1:39 ± 0:21wt% Au ion was located in the
macrophage cells. That Au ion means that ANS was located inside the macrophage cell. The elemental imaging process of (a) empty
macrophage cells and (b) ANS-MAs indicated the Au ion site (macrophage cell shape was marked). The empty macrophage cell has no
detection of the Au ions (ANS: gold nanoshell; ANS-MAs: gold nanoshell-loaded macrophages).
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AST levels was shown in our ANS-MAs, suggesting that
injection may prevent liver damage or malnutrition. Blood
urea nitrogen (BUN) and creatinine, which indicate healthy
kidney function, were also in the normal range. Importantly,
normal urea levels in the blood indicate normal kidney and
liver functions. And the complete blood count (CBC) was
performed at regular intervals (Figure 7). These results,
including serum biochemistry and CBC, indicate normal
liver function, as the values are all within normal ranges.
These findings support the use of macrophages for nanopar-
ticle or drug delivery in vivo.
The histological analysis, which identifies ANS-MA tox-
icity, was performed to detail the micromorphology and his-
tological evaluation of tissue interactions. Figure 8 provides a
visual observation of inflammation and histological interac-
tions in ANS-MAs. The rat heart tissue shows no significant
appearance of hyperemia in the mesenchyme, with no infil-
tration of inflammatory corpuscles including lymphocytes,
neutrophilic granulocytes, or eosinophil granulocytes. Infil-
tration of the inflammatory signs was not detected in the lung
tissue image. The image of liver tissue was normal with
hepatic lobules intact. Additionally, the symptoms of swell-
ing, degeneration, necrosis, and infiltration of inflammatory
corpuscles were not detected in the liver. In the kidneys, the
size of the renal glomerulus was normal, and no inflamma-
tory corpuscles or urinary cylinders were found. In summary,
no apparent histopathological abnormalities, lesions, or
necroses were observed in the heart, lungs, liver, or kidneys
during the 21-day period.
4. Discussion
Photothermal therapy is based on the resonant photon
energy absorbed with light irradiation, resulting in the rapid
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generation of heat on the surface of the nanoparticles, which
damages and destroys cancer cells. The therapeutic strategy
of PTT with nanoparticles provides localized, targeted heat-
ing and cytotoxic treatment which can potentially offer more
functional and aesthetic results [2, 26, 27]. ANS have an
absorption in the NIR region; however, most biological tis-
sues lack NIR-absorbing chemophores [10, 26]. Therefore,
normal tissue around the tumor might suffer minimal ther-
mal damage. In the case of an ANS having a maximum
absorption peak at 800-810 nm (Figure 1(b)), which falls
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Figure 4: (a) The spheroid growth effect depends on the ratio of ANS-MAs with PTT. Spheroids were irradiated with 810 nm laser light for
10min at an irradiance of 14W/cm2. The values shown represent the average spheroid diameter 14 days postphotothermal treatment as a %
increase of the initial size. Complete growth inhibition was observed at a FaDu : ANS-MA ratio of 4 : 1. (b) Kinetics of spheroid growth
following PTT. PTT of spheroids containing ANS-MAs resulted in a decrease in the spheroid volume. In contrast, the untreated spheroids
and spheroids containing empty macrophage continued to increase in volume (PTT: photothermal therapy; Ma: macrophage; ANS-MAs:
gold nanoshell-loaded macrophages).
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Figure 6: Time-dependent serum biochemistry results, from rats treated with the ANS-MAs for 21 days. Those results indicate mean of (a)
albumin, (b) ALP, (c) ALT, (d) AST, (e) BUN, (f) creatinine, (g) globulin, and (h) total protein. Additionally, the values of T.Bil and γ-GTP
were lower than the detection value (<1 and <3) (N-number: 7; ALP: alkaline phosphatase; ALT: alanine aminotransferase; BUN: blood urea
nitrogen; T.Bil: total bilirubin; γ-GTP: gamma-glutamyl transferase; ANS-MAs: gold nanoshell-loaded macrophages).
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within the first NIR window (650–850 nm), it can safely pen-
etrate 2-3 cm of the tissue [28]. This penetration depth was
hard to apply to the internal organs (including the brain,
heart, liver, kidney, and spleen), but HNSCC is a suitable type
due to the shallow penetration depth of light [29, 30].
ANS have been the subject of intense scrutiny due to their
potential PTT application. However, the clinical use of nano-
particles for HNSCC treatment requires specific targeted
delivery and biocompatibility. Recent research has focused
on the macrophage as a delivery vessel for the targeted nano-
medicine approach in cancer therapy, as it may provide
enhanced therapeutic efficiency and reduced toxicity. The
macrophage can cause migration and reaction in tumor
development [11]. Additionally, the macrophage phagocyto-
ses the ANS. The strategy of implementing a biomimetic
macrophage delivery system would provide a nontoxic
option that yields a high uptake ratio of nanoparticles [21].
In this study, ANS was PEGylated to increase the
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Figure 7: Time-dependent complete blood count test, which from rats treated with the ANS-MAs for 21 days. The values of WBC are
increasing the control due to the injected macrophage cells. The values of (a) RBC, (b) WBC, (c) Hct, (d) Hb, and (e) platelets are the
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biocompatibility of gold, and a sufficient quantity of ANS
was taken up by the macrophage to provide efficient
PTT. Phagocytosis of the ANS was observed when incu-
bated with the macrophage for 24 hours. The ANS loca-
tions were indicated by their optical, reflective index, and
gold ion (Figures 1 and 2, and S1 and Video 1). Another
cell-based delivery modality, cell-membrane-coating nano-
technology, has been widely applied in PTT [31]. Even
though it has a remarkable ability to interact with its bio-
logical environment, cell-membrane-coating nanotechnol-
ogy had some limitations as it can disrupt the structure
of the cell membrane [31, 32]. This method involved com-
plicated manufacturing steps. Additionally, nanomaterials
used in cell-membrane-coating technology had uncon-
trolled membrane structure, and this method had low
nanoparticle uptake ratio. Therefore, in order to circum-
vent the issues associated with cell-membrane-coating
technique and to ensure certain advantages, we used live
macrophages in this study. ANS-MAs were biocompatible,
easy to prepare by coculturing macrophages with nanopar-
ticles, and had high nanoparticle absorption. Additionally,
the migration properties of ANS-MAs were similar to
those of live macrophages [31]. One important feature of
hyperthermia with PTT is the hypoxic cell distribution in
the center of tumors. It is susceptible to hyperthermia
death due to its oxygen-independent condition. This
hyperthermia induces the necrosis of cancer cells with pro-
tein denaturation [2, 28, 33]. At temperatures greater than
43°C, protein denaturation and disruption of the cellular
membrane occur, and some studies have shown ablation
of tumor tissues [29, 34, 35]. Cytotoxic effects have been
demonstrated in cells maintained at 42°C for 1 h, and irre-
versible cellular damage occurs when temperatures are
increased to 46°C for 1 h [36]. This duration can be short-
ened to only 4-6min using higher temperatures of 50-52°C
[36, 37]. Yang et al. have reported that thermally induced
injury and death of cancer cells begin at 44°C to 45°C,
which was achieved using the PTT effect with gold NS
and irradiation with an NIR laser at a power of 2W for
5min [38, 39]. It can be expected, then, that the PTT strat-
egy using the ANS-MAs can induce the apoptosis and cell
death progress. As the results of this study show, apoptosis
and death values increased in correlation with the ANS-
MA ratio (Figure 5).
Moreover, the biocompatibility of the ANS-MA system is
an important factor in evaluating the therapeutic potential of
the new drug-delivery system. Because biocompatibility is a
critical property for blood-contacting materials, it must be
examined prior to clinical use [40]. In recent decades, a
majority of nanotoxicity research has focused on cell-based
examination. However, these analysis studies can be mislead-
ing, so they require verification with in vivo animal experi-
ments [41]. Several studies on the biodistribution of gold
nanoparticles have shown that most gold nanoparticles pre-
dominantly accumulate in organs such as the liver and lung
after intravenous administration. These studies revealed that
the distribution of gold nanoparticles was size dependent [42,
43]. We traced gold nanoparticle-loaded macrophages in a
Control Day 1 Day 7 Day 21
Heart
Lung
Liver
Kidney
Figure 8: Histology study of the rats treated with the ANS-MAs for 21 days. Histological evaluation of the major organs (heart, lung, liver,
and kidney) of the rat at 1, 7, and 21 days after intravenous injection of the ANS-MAs. No symptoms of inflammation and/or lesion were
observed in the images. Images were taken at ×40 (heart) and ×100 (lung, liver, and kidney) magnification. (ANS-MAs: gold nanoshell-
loaded macrophages).
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mouse model. The results indicated that macrophages accu-
mulated significantly in the lungs and liver, from 1 to 6 hours
after intravenous administration of ANS-MAs, and were
removed from each organ at 24 hours (data not shown). In
vivo toxicology studies have been established to confirm the
biocompatibility property of ANS-MAs. The hematology test
was used to indicate the hemocompatibility of the system by
determining whether or not a hemolytic reaction was
induced. The hemolytic reaction can be caused by immune
hemolysis and/or nonimmune hemolysis. According to the
guide for the evaluation of biocompatible materials, the
hemolysis rate should be less than 5% [40]. In the serum bio-
chemistry, the six important factors that indicate hepatic
function include albumin, globulin, glutamic pyruvate trans-
aminase (GTP), alkaline phosphatase (ALP), total bilirubin
(TB), and total protein. Normal values for each of these indi-
cate no damage to the liver (Figure 6) [41]. A complete blood
count (CBC) was performed at regular intervals, and the
results suggest no acute toxicity (Figure 7) [44]. And the his-
tological studies suggest that ANS-MAs do not burden the
heart, lungs, liver, or kidneys, organs to which damage can
induce toxic responses (Figure 8) [40]. In other animal model
toxicology studies of intravenously injected silica nanoparti-
cles, hepatocyte necrosis and mononuclear inflammation at
the portal area were observed [45], indicating the possibility
of liver toxicity due to silica nanoparticles. Metal-based
photothermal nanoagents, such as CuS, had some limitations
associated with toxicity [31, 46]. Feng et al. [31] have sug-
gested that CuS-based nanoparticles can serve as promising
photothermal agents; however, their biodistribution study
showed that intravenously administrated CuS nanomaterials
were mainly present in the spleen, liver, and lung, organs that
are responsible for eliminating pathogens via the reticuloen-
dothelial system (RES). These results suggest that CuS can
potentially show organ toxicity. Our findings provide sub-
stantial evidence for the safety of ANS-MAs for biomedical
applications. Our results show that ANS-MAs can be
regarded as biologically safe. Furthermore, no acute toxicity
or morphological changes were noted from our cytotoxicity
studies as determined by the hematology test, in vivo serum
biochemistry, CBC, and histological studies.
In this study, ANS, which can maximize the hyperther-
mia in PTT, were used as part of a PTT strategy to treat the
HNSCC. To determine the possibility of using ANS-MAs as
a cancer therapy, we prepared the ANS-MAs by rat macro-
phage (NR8383, Figure 1(a)). These ANS-MAs were set into
tumor and macrophage spheroid models to measure PTT
efficacy. The efficacy of PTT depends on a number of factors,
including ANS concentration in the target tissue, laser power
density, exposure time, and blood perfusion. In the present
study, significant spheroid growth inhibition occurred in
hybrid spheroids of tumor and ANS-MAs compared with
spheroids containing empty macrophages. The dependence
of PTT efficacy on the number of loaded macrophages in
hybrid spheroids was investigated, and significant growth
suppression was observed in spheroids consisting of 20%
loaded macrophage, whereas complete growth cessation
was observed at a concentration of 25% loaded macrophage
(Figure 4). The cell hybrid spheroid model closely resembles
the real cancer environment and provides precise measure-
ments of therapeutic potential of our system. Toxicology
studies predict that nanotechnology-mediated immune cell
systems can be applied to novel strategies to overcome the
limitations of various fabricated materials. As the present
research shows, this macrophage-based delivery and protec-
tion strategy provides enhanced biocompatibility and a min-
imally invasive modality for cancer therapy in the medical
and pharmacological fields.
5. Conclusion
This ANS-MA system is able to be prepared easily, protects
the therapeutic agents from the blood immune system, and
enhances the effect of PTT on HNSCC. In this study, ANS
were successfully localized in the macrophage, and their
physical and photoabsorption properties were steadfast.
The tumor and macrophage hybrid model analysis indicated
powerful ANS-based PTT efficacy under NIR laser irradia-
tion. In vivo toxicology results suggest that ANS-MA could
be a promising candidate for a biocompatible strategy to
overcome the limitations of fabricated nanomaterials. This
ANS-MA delivery and PTT system strategy may work syner-
gistically with other therapy strategies, and it may potentially
improve the quality of life of patients with HNSCC by pro-
viding a minimally invasive modality for cancer treatment.
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(ANS: gold nanoshell; AuNP: gold nanoparticles). Figure
S3: (A) the temperature variation graph of the photothermal
efficiency of ANS-MAs. Temperature change was induced by
irradiating the ANS-MAs using an 810nm laser. Then, the
ANS-MAs were allowed to slowly cool down to surrounding
temperature (30°C) after turning off the laser. (B) Linear fit-
ting graph of the cooling time and temperature change data.
The photothermal conversion efficiency of ANS-MAs was
calculated using these data and graphs. (C) The temperature
change graph of ANS-MAs indicated that the photothermal
effect is stable for 5 cycles. The cycle involved irradiation
for 10min and blackout 10min (total 5 times). Figure S4:
hemoglobin release profile from the RBCs, which are exposed
to ANS-MAs. The value was measured from the absorbance
parameter of the RBC supernatant. PBS and Triton X-100
were used to each negative and positive control, respectively
(RBC: red blood cell; ANS: gold nanoshell; ANS-MAs: gold
nanoshell-loaded macrophages). ∗a: PBS (positive control);
b: macrophage; c-g: ANS-MAs (c–g: 12.5, 5, 2.5, 1.25, and
0.635 pmol of ANS/cells); h: Triton X-100 (negative control).
Supplementary 2. Video 1: holography image video of 3D
ANS-MAs. Red dots indicated the ANS location (ANS: gold
nanoshell; ANS-MAs: gold nanoshell-loaded macrophages).
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